COM:ERYTECH
PHAXIAM Therapeutics
- Stock
Last Close
0.80
28/06 15:35
Market Cap
48.66M
Beta: -
Volume Today
27.49K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '14 | Dec '15 | Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
revenue | 6.61M - | 10.78M 62.95% | 19.72M 82.99% | 1.33M - | |||||||
cost of revenue | 6.61M - | 10.78M 62.95% | 19.72M 82.99% | 25.46M 29.12% | 33.47M 31.44% | 52.19M 55.95% | 57.58M 10.32% | 1.61M - | |||
gross profit | -25.46M - | -33.47M 31.44% | -52.19M 55.95% | -57.58M 10.32% | -282K - | ||||||
selling and marketing expenses | 3.70M - | ||||||||||
general and administrative expenses | 4.36M - | 7.62M 74.63% | 6.66M 12.55% | 8.52M 27.99% | 14.60M 71.28% | 17.16M 17.56% | 14.97M 12.78% | 15.10M 0.88% | 13.89M 8.04% | 10.26M 26.10% | |
selling general and administrative expenses | 4.36M - | 7.62M 74.63% | 6.66M 12.55% | 8.52M 27.99% | 14.60M 71.28% | 17.16M 17.56% | 14.97M 12.78% | 15.10M 0.88% | 13.89M 8.04% | 13.97M 0.57% | |
research and development expenses | 52.19M - | 57.58M 10.32% | 45.10M 21.67% | 19.91M 55.86% | 9.84M 50.56% | ||||||
other expenses | -2.03M - | -2.81M 38.62% | -3.99M 42.06% | -3.10M 22.31% | -4.45M 43.50% | -5.28M 18.80% | -3.72M 29.62% | -3.69M 0.86% | -6.65M 80.33% | ||
cost and expenses | 8.95M - | 15.58M 74.15% | 22.39M 43.67% | 30.89M 37.95% | 43.62M 41.23% | 64.07M 46.89% | 68.83M 7.43% | 56.52M 17.89% | 27.15M 51.96% | 25.42M 6.37% | |
operating expenses | 2.34M - | 4.81M 105.87% | 2.67M 44.45% | 5.42M 103.11% | 10.15M 87.15% | 64.07M 531.08% | 68.83M 7.43% | 56.52M 17.89% | 27.15M 51.96% | 23.81M 12.30% | |
interest expense | 6.80K - | 5K 26.48% | 4K 20% | 15K 275% | 9K 40% | 1.53M 16,933.33% | 5.35M 249.25% | 2.14M 60.07% | 1.36M 36.20% | 196K 85.63% | |
ebitda | -8.60M - | -14.72M 71.26% | -21.47M 45.85% | -32.99M 53.61% | -37.42M 13.43% | -61.13M 63.37% | -67.94M 11.15% | -47.45M 30.15% | -22.69M 52.18% | -23.81M 4.91% | |
operating income | -8.95M - | -15.58M 74.15% | -22.39M 43.67% | -30.89M 37.95% | -43.62M 41.23% | -64.07M 46.89% | -68.83M 7.43% | -56.52M 17.89% | -2.80M 95.05% | -25.42M 809.05% | |
depreciation and amortization | 276.52K - | 288K 4.15% | 425K 47.57% | 532K 25.18% | 797K 49.81% | 2.95M 269.76% | 889K 69.83% | 9.06M 919.12% | -19.90M 319.62% | 1.61M 108.08% | |
total other income expenses net | 68.17K - | 568K 733.19% | 488K 14.08% | -2.65M 642.21% | 5.40M 304.04% | 1.41M 73.81% | -4.46M 415.77% | 2.72M 160.92% | 3.09M 13.57% | 683K 77.89% | |
income before tax | -8.88M - | -15.02M 69.10% | -21.90M 45.86% | -33.53M 53.10% | -38.22M 13.98% | -62.66M 63.94% | -73.30M 16.98% | -53.80M 26.61% | 293K 100.54% | -24.73M 8,541.64% | |
income tax expense | -20.16K - | -3K 85.12% | 10K 433.33% | -3K 130% | 2K 166.67% | -1K 150% | 3K 400% | 2K 33.33% | 521K 25,950% | -1.25M 339.16% | |
net income | -8.86M - | -15.01M 69.45% | -21.91M 45.96% | -33.53M 53.01% | -38.22M 14.00% | -62.66M 63.93% | -73.30M 16.98% | -53.80M 26.61% | -228K 99.58% | -23.49M 10,201.75% | |
weighted average shs out | 5.87M - | 6.96M 18.43% | 7.98M 14.75% | 17.94M 124.68% | 17.94M 0.00% | 17.94M 0.00% | 18.39M 2.50% | 23.69M 28.86% | 31.02M 30.91% | 5.08M 83.62% | |
weighted average shs out dil | 5.87M - | 6.96M 18.43% | 7.98M 14.75% | 17.94M 124.68% | 17.94M 0.00% | 17.94M 0.00% | 18.39M 2.50% | 23.69M 28.86% | 31.02M 30.91% | 5.08M 83.62% | |
eps | -1.51 - | -2.16 43.05% | -2.74 26.85% | -1.87 31.75% | -2.13 13.90% | -3.49 63.85% | -3.99 14.33% | -2.27 43.11% | -0.01 99.67% | -4.62 62,332.43% | |
epsdiluted | -1.51 - | -2.16 43.05% | -2.74 26.85% | -1.87 31.75% | -2.13 13.90% | -3.49 63.85% | -3.99 14.33% | -2.27 43.11% | -0.01 99.67% | -4.62 62,332.43% |
All numbers in EUR (except ratios and percentages)